|
Characteristic
|
PD-L1 expression in tumor cells [cases (%)]
|
P value
|
PD-L1 expression in tumor microenvironment [cases (%)]
|
P value
|
|---|
|
Negative
|
Positive
|
Negative
|
Positive
|
|---|
|
Total
|
104
|
100
| |
160
|
44
| |
|
Gender
| | |
0.22
| | |
0.34
|
|
Male
|
63 (60.6)
|
52 (52.0)
| |
93 (58.1)
|
22 (50.0)
| |
|
Female
|
41 (39.4)
|
48 (48.0)
| |
67 (41.9)
|
22 (50.0)
| |
|
Age (years)
| | |
0.78
| | |
0.92
|
|
≤ 60
|
73 (70.2)
|
72 (72.0)
| |
114 (71.2)
|
31 (70.5)
| |
|
> 60
|
31 (29.8)
|
28 (28.0)
| |
46 (28.8)
|
13 (29.5)
| |
|
Clinical stage
| | |
0.04
| | |
0.12
|
|
I–II
|
58 (55.8)
|
42 (42.0)
| |
83 (51.9)
|
17 (38.6)
| |
|
III–IV
|
46 (44.2)
|
58 (58.0)
| |
77 (48.1)
|
27 (61.4)
| |
|
B symptoms
| | |
0.74
| | |
0.22
|
|
No
|
75 (72.1)
|
70 (70.0)
| |
117 (73.1)
|
28 (63.6)
| |
|
Yes
|
29 (27.9)
|
30 (30.0)
| |
43 (26.9)
|
16 (36.4)
| |
|
Spleen involvement
| | |
0.19
| | |
0.22
|
|
No
|
92 (88.5)
|
82 (82.0)
| |
139 (86.9)
|
35 (79.5)
| |
|
Yes
|
12 (11.5)
|
18 (18.0)
| |
21 (13.1)
|
9 (20.5)
| |
|
IPI
| | |
0.09
| | |
0.18
|
|
< 3
|
86 (82.7)
|
73 (73.0)
| |
128 (80.0)
|
31 (70.5)
| |
|
≥ 3
|
18 (17.3)
|
27 (27.0)
| |
32 (20.0)
|
13 (29.5)
| |
|
Extranodal involvement
| | |
0.67
| | |
0.88
|
|
No
|
42 (40.4)
|
44 (44.0)
| |
67 (41.9)
|
19 (43.2)
| |
|
Yes
|
62 (59.6)
|
56 (56.0)
| |
93 (58.1)
|
25 (56.8)
| |
|
Bulky diseasea
| | |
0.91
| | |
0.82
|
|
No
|
56 (70.0)
|
63 (69.2)
| |
92 (69.2)
|
27 (71.1)
| |
|
Yes
|
24 (30.0)
|
28 (30.8)
| |
41 (30.8)
|
11 (28.9)
| |
|
LDHb (U/L)
| | |
0.25
| | |
0.27
|
|
≤ 245
|
55 (55.6)
|
44 (47.3)
| |
81 (53.6)
|
18 (43.9)
| |
|
> 245
|
44 (44.4)
|
49 (52.7)
| |
70 (46.4)
|
23 (56.1)
| |
|
ALPc (U/L)
| | |
0.17
| | |
0.42
|
|
≤ 110
|
93 (92.1)
|
86 (86.0)
| |
138 (87.9)
|
41 (93.2)
| |
|
> 110
|
8 (7.9)
|
14 (14.0)
| |
19 (12.1)
|
3 (6.8)
| |
|
β2-MGd (mg/L)
| | |
0.06
| | |
0.01
|
|
≤ 2.52
|
25 (69.4)
|
21 (48.8)
| |
41 (66.1)
|
5 (29.4)
| |
|
> 2.52
|
11 (30.6)
|
22 (51.2)
| |
21 (33.9)
|
12 (70.6)
| |
|
Ki-67e (%)
| | |
0.74
| | |
0.75
|
|
< 90
|
45 (61.6)
|
45 (64.3)
| |
70 (63.6)
|
20 (60.6)
| |
|
≥ 90
|
28 (38.4)
|
25 (35.7)
| |
40 (36.4)
|
13 (39.4)
| |
|
GCB subtypef
| | |
0.02
| | |
0.04
|
|
Non-GCB
|
61 (61.6)
|
77 (77.0)
| |
102 (65.8)
|
36 (81.8)
| |
|
GCB
|
38 (38.4)
|
23 (23.0)
| |
53 (34.2)
|
8 (18.2)
| |
|
Rituximabg
| | |
0.62
| | |
0.10
|
|
No
|
40 (43.0)
|
42 (46.7)
| |
59 (41.5)
|
23 (56.1)
| |
|
Yes
|
53 (57.0)
|
48 (53.3)
| |
83 (58.5)
|
18 (43.9)
| |
|
First-line chemotherapy CRh
| | |
0.61
| | |
0.15
|
|
No
|
31 (33.7)
|
31 (36.9)
| |
46 (32.6)
|
16 (45.7)
| |
|
Yes
|
61 (66.3)
|
53 (63.1)
| |
95 (67.4)
|
19 (54.3)
| |
|
First-line chemotherapy resistancei
| | |
0.36
| | |
0.03
|
|
No
|
83 (90.2)
|
72 (85.7)
| |
128 (90.8)
|
27 (77.1)
| |
|
Yes
|
9 (9.8)
|
12 (14.3)
| |
13 (9.2)
|
8 (22.9)
| |
|
Relapse
| | |
0.12
| | |
0.93
|
|
No
|
89 (85.6)
|
77 (77.0)
| |
130 (81.2)
|
36 (81.8)
| |
|
Yes
|
15 (14.4)
|
23 (23.0)
| |
30 (18.8)
|
8 (18.2)
| |
|
Death
| | |
0.09
| | |
0.34
|
|
No
|
69 (66.3)
|
55 (55.0)
| |
100 (62.5)
|
24 (54.5)
| |
|
Yes
|
35 (33.7)
|
45 (45.0)
| |
60 (37.5)
|
20 (45.5)
| |
-
IPI international prognostic index, LDH lactate dehydrogenase, ALP anaplastic lymphoma kinase, β2-MG β2-microglobulin, GCB germinal center B-cell-like, CR complete remission
-
aThe data of 33 patients were missing
-
bThe data of 12 patients were missing
-
cThe data of 3 patients were missing
-
dThe data of 125 patients were missing
-
eThe data of 61 patients were missing
-
fThe data of 5 patients were missing
-
gThe data of 21 patients were missing
-
hThe data of 28 patients were missing
-
iThe data of 28 patients were missing
